These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 35649958)

  • 21. Effect of dexamethasone in patients with ARDS and COVID-19 - prospective, multi-centre, open-label, parallel-group, randomised controlled trial (REMED trial): A structured summary of a study protocol for a randomised controlled trial.
    Maláska J; Stašek J; Duška F; Balík M; Máca J; Hruda J; Vymazal T; Klementová O; Zatloukal J; Gabrhelík T; Novotný P; Demlová R; Kubátová J; Vinklerová J; Svobodník A; Kratochvíl M; Klučka J; Gál R; Singer M;
    Trials; 2021 Mar; 22(1):172. PubMed ID: 33648568
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The rationale of using mesenchymal stem cells in patients with COVID-19-related acute respiratory distress syndrome: What to expect.
    Can A; Coskun H
    Stem Cells Transl Med; 2020 Nov; 9(11):1287-1302. PubMed ID: 32779878
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Promising role for mesenchymal stromal cells in coronavirus infectious disease-19 (COVID-19)-related severe acute respiratory syndrome?
    Hamdan H; Hashmi SK; Lazarus H; Gale RP; Qu W; El Fakih R
    Blood Rev; 2021 Mar; 46():100742. PubMed ID: 32854985
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mesenchymal stromal cell therapy for COVID-19-induced ARDS patients: a successful phase 1, control-placebo group, clinical trial.
    Kaffash Farkhad N; Sedaghat A; Reihani H; Adhami Moghadam A; Bagheri Moghadam A; Khadem Ghaebi N; Khodadoust MA; Ganjali R; Tafreshian AR; Tavakol-Afshari J
    Stem Cell Res Ther; 2022 Jun; 13(1):283. PubMed ID: 35765103
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Phase 3 Randomized Study of Remestemcel-L versus Placebo Added to Second-Line Therapy in Patients with Steroid-Refractory Acute Graft-versus-Host Disease.
    Kebriaei P; Hayes J; Daly A; Uberti J; Marks DI; Soiffer R; Waller EK; Burke E; Skerrett D; Shpall E; Martin PJ
    Biol Blood Marrow Transplant; 2020 May; 26(5):835-844. PubMed ID: 31505228
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness of Mesenchymal Stem Cell Therapy for COVID-19-Induced ARDS Patients: A Case Report.
    Kim K; Bae KS; Kim HS; Lee WY
    Medicina (Kaunas); 2022 Nov; 58(12):. PubMed ID: 36556900
    [No Abstract]   [Full Text] [Related]  

  • 27. A Phase 3, Single-Arm, Prospective Study of Remestemcel-L, Ex Vivo Culture-Expanded Adult Human Mesenchymal Stromal Cells for the Treatment of Pediatric Patients Who Failed to Respond to Steroid Treatment for Acute Graft-versus-Host Disease.
    Kurtzberg J; Abdel-Azim H; Carpenter P; Chaudhury S; Horn B; Mahadeo K; Nemecek E; Neudorf S; Prasad V; Prockop S; Quigg T; Satwani P; Cheng A; Burke E; Hayes J; Skerrett D;
    Biol Blood Marrow Transplant; 2020 May; 26(5):845-854. PubMed ID: 32018062
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of MSC in Patients with Severe COVID-19: Analysis of the Literature and a Case Study.
    Grumet M; Sherman J; Dorf BS
    Stem Cells Transl Med; 2022 Nov; 11(11):1103-1112. PubMed ID: 36181766
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunomodulation of Mesenchymal Stem Cells in Acute Lung Injury: From Preclinical Animal Models to Treatment of Severe COVID-19.
    Li JP; Wu KH; Chao WR; Lee YJ; Yang SF; Chao YH
    Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897770
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Promise of Mesenchymal Stem Cells Therapy for Acute Respiratory Distress Syndrome Caused by COVID-19.
    Gu J; Zhao Q; Han Z; Han Z
    Curr Stem Cell Res Ther; 2021; 16(3):277-285. PubMed ID: 32729428
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Remestemcel-L Therapy for COVID-19-Associated Multisystem Inflammatory Syndrome in Children.
    Eckard AR; Borow KM; Mack EH; Burke E; Atz AM
    Pediatrics; 2021 May; 147(5):. PubMed ID: 33579813
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Visualized Analyses of Investigations Upon Mesenchymal Stem/stromal Cell-based Cytotherapy and Underlying Mechanisms for COVID-19 Associated ARDS.
    Aitong W; Leisheng Z; Hao Y
    Curr Stem Cell Res Ther; 2022; 17(1):2-12. PubMed ID: 34254927
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunomodulatory and Anti-fibrotic Effects Following the Infusion of Umbilical Cord Mesenchymal Stromal Cells in a Critically Ill Patient With COVID-19 Presenting Lung Fibrosis: A Case Report.
    da Silva KN; Pinheiro PCG; Gobatto ALN; Passos RDH; Paredes BD; França LSA; Nonaka CKV; Barreto-Duarte B; Araújo-Pereira M; Tibúrcio R; Cruz FF; Martins GLS; Andrade BB; de Castro-Faria-Neto HC; Rocco PRM; Souza BSF
    Front Med (Lausanne); 2021; 8():767291. PubMed ID: 34869480
    [No Abstract]   [Full Text] [Related]  

  • 34. Therapeutic mechanisms of mesenchymal stem cells in acute respiratory distress syndrome reveal potentials for Covid-19 treatment.
    Wang W; Lei W; Jiang L; Gao S; Hu S; Zhao ZG; Niu CY; Zhao ZA
    J Transl Med; 2021 May; 19(1):198. PubMed ID: 33971907
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of the safety and efficacy of using human menstrual blood-derived mesenchymal stromal cells in treating severe and critically ill COVID-19 patients: An exploratory clinical trial.
    Xu X; Jiang W; Chen L; Xu Z; Zhang Q; Zhu M; Ye P; Li H; Yu L; Zhou X; Zhou C; Chen X; Zheng X; Xu K; Cai H; Zheng S; Jiang W; Wu X; Li D; Chen L; Luo Q; Wang Y; Qu J; Li Y; Zheng W; Jiang Y; Tang L; Xiang C; Li L
    Clin Transl Med; 2021 Feb; 11(2):e297. PubMed ID: 33634996
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hypothesis for the management and treatment of the COVID-19-induced acute respiratory distress syndrome and lung injury using mesenchymal stem cell-derived exosomes.
    Taghavi-Farahabadi M; Mahmoudi M; Soudi S; Hashemi SM
    Med Hypotheses; 2020 Nov; 144():109865. PubMed ID: 32562911
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness of Mesenchymal Stem Cell Therapy for COVID-19 Patients in the Intensive Care Unit: A Case-Control Study.
    Canbaz H; İdiz UO; Cankar Dal H; Kaçıroğlu F; Taş S; Çubukçu HC; Beştemir A; Gülşen M; Polat İT; Laloğlu A; Tör İH; Akkurt HE; Ateş U; Reisli İ; Koç E; İnkaya AÇ; Karakükçü M; Ceylan M; Haznedaroğlu İC; Akın H
    Turk J Haematol; 2022 Dec; 39(4):222-229. PubMed ID: 36250478
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of COVID-19-associated ARDS with mesenchymal stromal cells: a multicenter randomized double-blind trial.
    Monsel A; Hauw-Berlemont C; Mebarki M; Heming N; Mayaux J; Nguekap Tchoumba O; Diehl JL; Demoule A; Annane D; Marois C; Demeret S; Weiss E; Voiriot G; Fartoukh M; Constantin JM; Mégarbane B; Plantefève G; Malard-Castagnet S; Burrel S; Rosenzwajg M; Tchitchek N; Boucher-Pillet H; Churlaud G; Cras A; Maheux C; Pezzana C; Diallo MH; Ropers J; Menasché P; Larghero J;
    Crit Care; 2022 Feb; 26(1):48. PubMed ID: 35189925
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Overview of Stem Cell Therapy for Acute Respiratory Distress Syndrome with Focus on COVID 19.
    Kaye RJ
    Pain Physician; 2020 Aug; 23(4S):S421-S432. PubMed ID: 32942797
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mesenchymal stromal cells reduce evidence of lung injury in patients with ARDS.
    Wick KD; Leligdowicz A; Zhuo H; Ware LB; Matthay MA
    JCI Insight; 2021 Jun; 6(12):. PubMed ID: 33974564
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.